Emergent Biosolutions Inc. $EBS Position Increased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Emergent Biosolutions Inc. (NYSE:EBS) by 5.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 986,673 shares of the biopharmaceutical company’s stock after buying an additional 55,046 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 1.82% of Emergent Biosolutions worth $6,295,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Janney Montgomery Scott LLC bought a new stake in shares of Emergent Biosolutions during the 2nd quarter worth $68,000. PFG Investments LLC purchased a new stake in shares of Emergent Biosolutions during the second quarter valued at $73,000. SBI Securities Co. Ltd. boosted its position in shares of Emergent Biosolutions by 95.1% in the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 6,313 shares during the period. Public Employees Retirement System of Ohio increased its stake in Emergent Biosolutions by 135.9% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 13,181 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 7,593 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in Emergent Biosolutions in the 1st quarter worth about $70,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Insider Activity at Emergent Biosolutions

In other news, Director Kathryn C. Zoon sold 7,086 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the transaction, the director owned 71,799 shares in the company, valued at $636,857.13. This represents a 8.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Coleen Glessner sold 30,608 shares of the firm’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total transaction of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares in the company, valued at $1,443,190. This represents a 17.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EBS shares. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. Finally, Wall Street Zen upgraded Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Emergent Biosolutions currently has an average rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Stock Performance

Shares of NYSE EBS opened at $10.80 on Thursday. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. Emergent Biosolutions Inc. has a one year low of $4.02 and a one year high of $13.41. The business’s 50-day moving average price is $9.26 and its two-hundred day moving average price is $7.72. The company has a market capitalization of $566.95 million, a P/E ratio of 8.30 and a beta of 2.05.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The firm had revenue of $222.50 million for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 21.43%. Emergent Biosolutions has set its FY 2023 guidance at EPS. Analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.